Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation

Launched by XIAO-MING MAO · May 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the connection between a virus called Epstein-Barr Virus (EBV) and a condition known as Graves' Disease (GD), which affects the thyroid and can cause symptoms like rapid heartbeat and weight loss. The researchers want to understand how reactivation of this virus might lead to new cases of Graves' Disease or cause it to come back after treatment. They will look at blood samples from patients who have recently been diagnosed with Graves' Disease or who have experienced a return of their symptoms after treatment.

To be eligible for this study, participants should be between the ages of 18 and 65 and must have been diagnosed with Graves' Disease or have had their symptoms return after treatment with antithyroid medications. Patients with other specific conditions, like certain thyroid disorders or serious health issues, will not be included in the trial. Those who participate can expect to undergo various tests to check their thyroid function and to look for signs of the EBV virus. The trial is currently not recruiting participants, so if you're interested, it's a good idea to keep an eye out for when it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The clinical evaluation included patient history, physical examination, and thyroid ultrasonography. Laboratory and diagnostic testing included determination of serum levels of free thyroxine (FT4), T3 ( FT3), thyrotropin (TSH), TPOAb, TGAb, and serum levels of thyrotropin receptor antibody (TRAb).
• Exclusion Criteria:
• • Patients with subacute thyroiditis, hyperfunctioning thyroid nodules, iodine hyperthyroidism, drug-induced hyperthyroidism, or other causes of hyperthyroidism were also excluded. The exclusion criteria for both patients with GD included diabetes, infectious diseases, other chronic diseases, and cancer.